Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study-Reference-Cited by-同舟云学术

Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study

Published:2022-06-02 Issue:3 Volume:11 Page:1193-1208
ISSN:2193-8253
Container-title:Neurology and Therapy
language:en
Short-container-title:Neurol Ther

Author:

Petracca Maria,Ruggieri Serena^ORCID,Barbuti Elena,Ianniello Antonio,Fantozzi Roberta,Maniscalco Giorgia Teresa,Andreone Vincenzo,Landi Doriana,Marfia Girolama Alessandra,Di Gregorio Maria,Iodice Rosa,Sinisi Leonardo,Maida Elisabetta,Missione Rosanna,Coppola Cinzia,Bonavita Simona,Borriello Giovanna,Centonze Diego,Lus Giacomo,Pozzilli Carlo,Signoriello Elisabetta

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

https://link.springer.com/content/pdf/10.1007/s40120-022-00364-6.pdf

Reference39 articles.

1. Jacobs BM, Ammoscato F, Giovannoni G, Baker D, Schmierer K. Cladribine: mechanisms and mysteries in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2018;89:1266–71.

2. Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, et al. Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler J. 2018;24:1594–604.

3. De Stefano N, Sormani MP, Giovannoni G, Rammohan K, Leist T, Coyle PK, et al. Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: the CLARITY and CLARITY Extension studies. Mult Scler J. 2022;28:111–20.

4. Giovannoni G, Singer BA, Issard D, Jack D, Vermersch P. Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: the CLARITY extension study. Mult Scler J. 2021. https://doi.org/10.1177/13524585211049392.

5. Giovannoni G, Comi G, Rammohan K, Rieckmann P, Dangond F, Keller B, et al. Long-term disease stability assessed by the expanded disability status scale in patients treated with cladribine tablets 3.5 mg/kg for relapsing multiple sclerosis: an exploratory post hoc analysis of the CLARITY and CLARITY extension studies. Adv Ther. 2021;38:4975–85.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cladribine use trend in Latin America: the changes in patient profile impact in the drug effectiveness;Neurological Sciences;2024-09-11

2. Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: A real-world, single Centre study considering a two-year interval from year-2 dosing;Journal of the Neurological Sciences;2024-07

3. Early clinical effect of cladribine in patients with highly active multiple sclerosis in Mexico;Multiple Sclerosis Journal - Experimental, Translational and Clinical;2024-07

4. Prospective observational study to evaluate treatment satisfaction and effectiveness in patients with relapsing multiple sclerosis starting cladribine tablets (CLADREAL) in Italy;Frontiers in Neurology;2024-04-04

5. Pregnancy effect on disease activity in women with multiple sclerosis treated with cladribine;Journal of Neurology;2024-04-03